Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
Nail lichen planus (NLP) is a chronic inflammatory disease that presents a significant therapeutic challenge. It can progress rapidly, leading to impaired nail morphology and function. Currently, there is no established standard therapy due to limited efficacy or potential for significant adverse reactions. In this report, we present a case of very severe NLP successfully treated with the Janus kinase 1 (JAK1) inhibitor abrocitinib, with no associated discomfort.
Authors
- Y. X. Luo (ORCID: https://orcid.org/0000-0001-9976-8447)
- Xingyun Zhao
- Ping Yang (ORCID: https://orcid.org/0000-0001-5256-026X)
- Liming Wu (ORCID: https://orcid.org/0000-0002-4708-0883)
- Jian Wu (ORCID: https://orcid.org/0000-0003-4518-7027)
- YunMi Qiu (ORCID: https://orcid.org/0000-0001-8077-306X)
- Jianbo Zhong (ORCID: https://orcid.org/0000-0002-4414-5944)
Institutions
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/ccid.s520633
- Citations
- 3
- Primary Topic
- Oral Health Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.40